Background: The coexistence of primary hyperparathyroidism (PHPT) and giant toxic nodular goiter is very rare. Moreover, PHPT could be easily overlooked because hyperthyroidism may also lead to hypercalcemia. A 99mTc-MIBI scan of the parathyroid glands is often negative when they are concomitant.

Case Presentation: Here, we report a rare case of the coexistence of giant toxic nodular goiter and PHPT that had been ignored for many years but was successfully treated with an ultrasound-guided parathyroid adenoma microwave ablation (MWA).

Conclusion: Reoperation for PHPT carries an increased risk of cure failure and complications. Thermal ablation has been proven effective in inactivating hyperfunctioning parathyroid lesions and in normalizing both serum parathyroid hormone (PTH) and calcium.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361506PMC
http://dx.doi.org/10.1186/s12902-022-01117-0DOI Listing

Publication Analysis

Top Keywords

giant toxic
12
toxic nodular
12
nodular goiter
12
coexistence primary
8
primary hyperparathyroidism
8
case report
4
report coexistence
4
hyperparathyroidism giant
4
goiter background
4
background coexistence
4

Similar Publications

Coverage bias in small molecule machine learning.

Nat Commun

January 2025

Chair for Bioinformatics, Institute for Computer Science, Friedrich Schiller University Jena, Jena, Germany.

Small molecule machine learning aims to predict chemical, biochemical, or biological properties from molecular structures, with applications such as toxicity prediction, ligand binding, and pharmacokinetics. A recent trend is developing end-to-end models that avoid explicit domain knowledge. These models assume no coverage bias in training and evaluation data, meaning the data are representative of the true distribution.

View Article and Find Full Text PDF

Pharmaceutical giants (e.g., Ashland, Bausch & Lomb, Johnson & Johnson, Medtronic, Neurelis, etc.

View Article and Find Full Text PDF

Emerging therapeutics in the management of tenosynovial giant cell tumor (TGCT).

Expert Rev Anticancer Ther

December 2024

Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA.

Article Synopsis
  • Tenosynovial giant cell tumors (TGCTs) are aggressive tumors often found in younger individuals, leading to long-term disability and typically managed via surgery, which has its own risks.
  • This review focuses on systemic treatment options, particularly for the diffuse subtype (DT-TGCT), and assesses recent advancements and the historical context of these therapies.
  • Notable progress includes the development of CSF1 receptor-targeting therapies like pexidartinib, paving the way for further research on treatment effectiveness and optimizing patient outcomes.
View Article and Find Full Text PDF

The secretions of Telodeinopus canaliculatus, a giant millipede, are used in traditional medicine to treat epileptic seizures. Therefore, this work aimed to assess the antiepileptogenic- and anxiolytic-like effects of an extract of T. canaliculatu in mice.

View Article and Find Full Text PDF

Comparative toxicities of commonly used agricultural insecticides to four honey bee species (Hymenoptera: Apidae) in Vietnam.

Environ Toxicol Pharmacol

January 2025

Department of Entomology and Plant Pathology, University of Arkansas, Fayetteville, AR 72701, USA. Electronic address:

Article Synopsis
  • * A study tested the oral toxicity of five common insecticides on four honey bee species, finding that the managed Asian honey bee (Apis cerana) showed the highest tolerance to these chemicals.
  • * The wild species, particularly the giant (A. dorsata) and red dwarf honey bee (A. florea), were more sensitive to the pesticides, emphasizing the need for better pesticide risk assessments and regulations to protect various honey bee species.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!